Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
NCT ID: NCT06245291
Last Updated: 2024-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2024-05-01
2024-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
NCT06154278
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
NCT06277037
A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)
NCT05808335
Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B
NCT02496897
Study of Safety and Tolerability of DCR HBVS
NCT03772249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at early and mid-treatment period timepoints
Imdusiran
subcutaneous injection
Durvalumab
intravenous injection
Cohort B
Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at mid and late-treatment period timepoints
Imdusiran
subcutaneous injection
Durvalumab
intravenous injection
Cohort C
Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at 2 late treatment period timepoints
Imdusiran
subcutaneous injection
Durvalumab
intravenous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imdusiran
subcutaneous injection
Durvalumab
intravenous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to provide informed consent
* Willing to follow protocol-specified contraception requirement
Exclusion Criteria
* Have or had liver cancer (hepatocellular carcinoma)
* Family history or personal history/current thyroid disease on or off replacement therapy
* Have a history or current autoimmune disease or has been on immunosuppressive medications within 6 months of the start of the study
* Females who are breastfeeding, pregnant or who wish to become pregnant during the study
* Known chronic or severe infection or recent significant exposure to infections such as tuberculosis or endemic mycosis, untreated latent infections like tuberculosis, or a positive or indeterminate QuantiFERON test.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arbutus Biopharma Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Infectious Diseases, AIDS and Clinical Immunology Research Center
Tbilisi, , Georgia
LLC "Neolab"
Tbilisi, , Georgia
Prince Of Wales Hospital - The Chinese University Of Hong Kong
Hong Kong, , Hong Kong
Queen Mary Hospital
Hong Kong, , Hong Kong
Punkt Zdrowia Hlebowicz Jakubowski Lekarze Spółka Partnerska
Gdansk, , Poland
ID Clinic Arkadiusz Pisula
Mysłowice, , Poland
Punkt Zdrowia Hlebowicz Jakubowski Lekarze Spółka Partnerska
Wroclaw, , Poland
Arensia Exploratory Medicine Srl Romania in colaborare cu Institutul National de Boli Infectioase
Bucharest, , Romania
Hospital Clínic de Barcelona
Barcelona, , Spain
Hospital Universitario Vall d'Hebron
Barcelona, , Spain
Chia-yi Christian Hospital
Chia-Yi City, , Taiwan
Kaohsiung Medical University Chung-ho Memorial Hospital
Kaohsiung City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
King Chulalongkorn Memorial Hospital
Bangkok, , Thailand
Siriraj Hospital
Bangkok, , Thailand
The Hiv Netherlands Australia Thailand Research Collaboration
Bangkok, , Thailand
Srinagarind Hospital
Khon Kaen, , Thailand
Naresuan University Hospital
Phitsanulok, , Thailand
Imperial College Hospital
London, , United Kingdom
Royal London Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AB-729-203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.